184 related articles for article (PubMed ID: 31366485)
1. The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines.
Goto W; Kashiwagi S; Asano Y; Takada K; Takahashi K; Fujita H; Takashima T; Shibutani M; Amano R; Tomita S; Hirakawa K; Ohira M
Anticancer Res; 2019 Aug; 39(8):4031-4041. PubMed ID: 31366485
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Takahashi K; Fujita H; Shibutani M; Amano R; Takashima T; Tomita S; Hirakawa K; Ohira M
BMC Cancer; 2020 Dec; 20(1):1215. PubMed ID: 33302911
[TBL] [Abstract][Full Text] [Related]
3. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
[TBL] [Abstract][Full Text] [Related]
4. Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.
Asano M; Matsui J; Towle MJ; Wu J; McGonigle S; DE Boisferon MH; Uenaka T; Nomoto K; Littlefield BA
Anticancer Res; 2018 Jun; 38(6):3375-3385. PubMed ID: 29848686
[TBL] [Abstract][Full Text] [Related]
5. The safety of eribulin for the treatment of metastatic breast cancer.
Perez-Garcia JM; Cortes J
Expert Opin Drug Saf; 2019 May; 18(5):347-355. PubMed ID: 31107111
[No Abstract] [Full Text] [Related]
6. Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.
Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 May; 38(5):2929-2938. PubMed ID: 29715119
[TBL] [Abstract][Full Text] [Related]
7. Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer.
Fujii T; Tokuda S; Nakazawa Y; Kurozumi S; Obayashi S; Yajima R; Shirabe K
In Vivo; 2020; 34(2):917-921. PubMed ID: 32111804
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
O'Shaughnessy J; Kaklamani V; Kalinsky K
Future Oncol; 2019 May; 15(14):1641-1653. PubMed ID: 30892083
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer.
de Nonneville A; Sabatier R; Gonçalves A; Extra JM; Tarpin C; Launay S; Tassy L; Viens P; Rousseau F
J Geriatr Oncol; 2018 May; 9(3):281-283. PubMed ID: 29174186
[No Abstract] [Full Text] [Related]
11. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
[TBL] [Abstract][Full Text] [Related]
12. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
13. ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
Oba T; Izumi H; Ito KI
Oncotarget; 2016 Oct; 7(43):70011-70027. PubMed ID: 27588398
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells.
Dezső Z; Oestreicher J; Weaver A; Santiago S; Agoulnik S; Chow J; Oda Y; Funahashi Y
PLoS One; 2014; 9(8):e106131. PubMed ID: 25171249
[TBL] [Abstract][Full Text] [Related]
15. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
[TBL] [Abstract][Full Text] [Related]
16. Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study.
Kobayashi T; Tomomatsu J; Fukada I; Shibayama T; Teruya N; Ito Y; Iwase T; Ohno S; Takahashi S
BMC Cancer; 2016 Jul; 16():404. PubMed ID: 27389013
[TBL] [Abstract][Full Text] [Related]
17. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E; Klaar S; Berglund EG; Salmonson T; Borregaard J; Hofland KF; Ersbøll J; Abadie E; Giuliani R; Pignatti F
Clin Cancer Res; 2012 Sep; 18(17):4491-7. PubMed ID: 22829199
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study.
Barni S; Livraghi L; Gravina A; Martella F; D'Onofrio L; Morritti M; Michelotti A; Vici P; Mentuccia L; Porcu L; Orditura M; Puglisi F;
J Geriatr Oncol; 2019 Nov; 10(6):990-993. PubMed ID: 31097340
[No Abstract] [Full Text] [Related]
19. Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report.
Falco I; Stragliotto S
Future Oncol; 2017 Apr; 13(11s):51-54. PubMed ID: 28481187
[TBL] [Abstract][Full Text] [Related]
20. Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
Ohtani S; Nakayama T; Yoshinami T; Watanabe KI; Hara F; Sagara Y; Kawaguchi H; Higaki K; Matsunami N; Hasegawa Y; Takahashi M; Mizutani M; Morimoto T; Sato M; Itoh M; Morita S; Masuda N
Breast Cancer; 2018 Jul; 25(4):438-446. PubMed ID: 29435730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]